A Missouri Study Finds Why Ageing Muscles Lose Strength, and a Drug Target That Reversed It in Animals

Researchers at the University of Missouri have identified a previously overlooked mechanical failure behind sarcopenia, the age-related loss of muscle strength that affects nearly half of adults over 80, and shown in animal models that a drug approach targeting it can restore some lost function. The study, led by W. David Arnold and published in the Journal of Clinical Investigation on 24 September, is described in a University of Missouri release carried by EurekAlert and in a summary from Futurity.

The nerve-muscle handoff, and where it breaks down

Every voluntary muscle contraction depends on a nerve signal crossing the neuromuscular junction, the point where a motor neuron meets a muscle fibre, and researchers had generally assumed this connection stayed reliable throughout life even as muscle mass itself declined. Arnold's team found otherwise: with age, muscle fibres lose NaV1.4, a sodium channel protein essential for propagating the electrical signal once it arrives from the nerve, meaning the junction can still fire correctly and the muscle can still fail to respond with full force, a distinct failure point from simple muscle wasting.

The fix that worked in animals

Working with the Danish biotechnology company NMD Pharma, the researchers tested an approach that partially inhibits a different channel, ClC-1, reasoning that dialling down its activity would make ageing muscle fibres more excitable and therefore more responsive to whatever nerve signal does arrive, compensating for the NaV1.4 shortfall rather than trying to restore it directly. Mizzou's own account of the discovery reports that this approach improved neuromuscular transmission and measurable muscle strength in aged rodents.

Evidence beyond the lab animals

Arnold has also been involved in a multicentre clinical trial of a ClC-1-targeting drug candidate called ignaseclant in patients with Charcot-Marie-Tooth disease, an inherited neuromuscular disorder unrelated to normal ageing but one that shares the same underlying channel biology. Data presented at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference showed measurable strength and functional gains in those patients, giving the Missouri team's animal results a human proof of concept for the drug mechanism, even though no trial has yet tested it specifically against age-related sarcopenia.

Why the distinction matters

Sarcopenia is usually treated as primarily a muscle problem, addressed through resistance exercise and protein intake aimed at preserving fibre mass. Arnold's findings reframe part of the condition as a signalling problem at the junction between nerve and muscle, which does not replace the case for exercise but does suggest a second, pharmacological lever that current treatment approaches are not pulling. Whether a ClC-1-targeting drug developed for a rare inherited disorder can be adapted and tested safely in older adults more broadly is a question the Missouri team's animal data has not yet answered, but it gives regulators and drug developers a specific, biologically grounded target to test against.